Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of ELX/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

NCT04183790 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT04183790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04183790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of ELX/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 3
Overall status
Completed
Start date
February 17, 2020
Completion date
February 24, 2024
Enrollment
64 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis